CA2426492A1 - Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer - Google Patents

Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2426492A1
CA2426492A1 CA002426492A CA2426492A CA2426492A1 CA 2426492 A1 CA2426492 A1 CA 2426492A1 CA 002426492 A CA002426492 A CA 002426492A CA 2426492 A CA2426492 A CA 2426492A CA 2426492 A1 CA2426492 A1 CA 2426492A1
Authority
CA
Canada
Prior art keywords
nmda
antagonist
treatment
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002426492A
Other languages
English (en)
Other versions
CA2426492C (fr
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2426492(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to CA002558708A priority Critical patent/CA2558708A1/fr
Publication of CA2426492A1 publication Critical patent/CA2426492A1/fr
Application granted granted Critical
Publication of CA2426492C publication Critical patent/CA2426492C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002426492A 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer Expired - Fee Related CA2426492C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002558708A CA2558708A1 (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200844 2002-05-31
DKPA200200844 2002-05-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002558708A Division CA2558708A1 (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
CA2426492A1 true CA2426492A1 (fr) 2003-09-16
CA2426492C CA2426492C (fr) 2006-10-03

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002426492A Expired - Fee Related CA2426492C (fr) 2002-05-31 2003-05-08 Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer

Country Status (9)

Country Link
KR (1) KR101016927B1 (fr)
CN (1) CN1655793A (fr)
AR (1) AR040121A1 (fr)
CA (1) CA2426492C (fr)
EA (1) EA007632B1 (fr)
IS (1) IS7558A (fr)
PE (1) PE20040623A1 (fr)
UA (1) UA82480C2 (fr)
ZA (1) ZA200409147B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294450A (zh) * 2014-05-29 2016-02-03 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
WO2018062941A1 (fr) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 Composition pharmaceutique pour la prévention ou le traitement d'une démence et d'un dysfonctionnement cognitif, contenant du donépézil ou un sel de qualité pharmaceutique de celui-ci et de la mémantine ou un sel de qualité pharmaceutique de celle-ci, et son procédé de préparation
KR20210072569A (ko) 2019-12-09 2021-06-17 주식회사 종근당 도네페질 및 메만틴을 포함하는 복합 제제

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294450A (zh) * 2014-05-29 2016-02-03 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用
CN105294450B (zh) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用

Also Published As

Publication number Publication date
AR040121A1 (es) 2005-03-16
EA007632B1 (ru) 2006-12-29
UA82480C2 (uk) 2008-04-25
KR101016927B1 (ko) 2011-02-28
EA200401617A1 (ru) 2005-06-30
IS7558A (is) 2004-11-26
KR20050024296A (ko) 2005-03-10
PE20040623A1 (es) 2004-09-11
ZA200409147B (en) 2006-06-28
CN1655793A (zh) 2005-08-17
CA2426492C (fr) 2006-10-03

Similar Documents

Publication Publication Date Title
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU7031500A (en) Therapeutic quinazoline compounds
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
BG107515A (en) Therapeutic combination
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GB0223040D0 (en) Therapeutic compounds
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
EP1201268A3 (fr) Compositions pharmaceutiques contenant des antagonistes du récepteur D4 de dopamine et des inhibiteurs de l' Acetylcholinesterase
HUP0400732A2 (hu) Gyógyászatilag hatékony uridin-észterek
AU3366297A (en) Polymorphic compounds
HUP0202862A2 (hu) A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
CA2282279A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazolinones pour le traitement des troubles neurodegeneratifs et des troubles lies a un traumatisme du systeme nerveux central
GB9907571D0 (en) Compounds
CA2426492A1 (fr) Combinaison d'un antagoniste nmda et d'agents inhibiteurs d'acetylcholinesterase pour le traitement de la maladie d'alzheimer
AU2907700A (en) Use of desoxypeganine in the treatment of alzheimer's dementia
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
NZ536111A (en) Statin therapy for enhancing cognitive maintenance
WO2004087157A3 (fr) Thérapie combinée destinée à la maladie d'alzheimer
WO2006020852A3 (fr) Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
AU6519596A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
WO2006020853A3 (fr) Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020850A3 (fr) Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140508